

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Suzy Jones

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Clinical Research Coordinator

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	Completion Date MM/YYYY	FIELD OF STUDY
University of Utah, Salt Lake City, UT University of Utah, Salt Lake City, UT	B.S. Minor	05/2012 05/2012	Exercise Science Nutrition

**A. Personal Statement**

I am a Clinical Research Coordinator and manager to the research team at the University of Utah in Pediatric Rheumatology, Immunology, and Allergy. During my time in this department, I have worked closely with Dr. Aimee Hersh and have assisted her in developing study protocols, databases, and source documentations. I have the experience, training, and motivation necessary to support the professional development of research coordinators. I have supervised, mentored and trained students and employees to perform all duties necessary to obtain informed consent from potential participants including screening and recruiting subjects, answering questions related to the study, and completion of study related documentation while monitoring enrollment goals and initiating strategies to promote enrollment and participant adherence to studies. My time as a business owner prepared me with the skills necessary to oversee all facets involved with running a research study including developing and monitoring budgets, and supervising and training employees. I have created new study IRB applications, amendments, and continuing reviews while maintaining compliance to protocols, HIPAA, and regulatory authority rules and regulations. I continually coordinate with PIs, Sponsors, CROs, IRB correspondences, laboratories, and other hospital personnel for all necessary study purposes while simultaneously overseeing over 20 research projects. While obtaining my BS in Exercise Physiology with a minor in Nutrition I discovered that I have a passion for research. I care about the quality of research; I care about the participants and their understanding about participation in research, and their rights as study participants. I feel strongly that everything we do in research today can affect the care of patients tomorrow. My hope is to further advance the success and quality of research.

**B. Positions and Honors**

**Positions and Employment**

- 2012            Research Assistant Trainer; University of Utah Department of Pediatrics, Salt Lake City, Utah
- 2013 – 2015   University of Utah Department of Pediatrics, Research Coordinator; Salt Lake City, Utah

- 2015-2018 University of Utah Department of Pediatrics, Division of Allergy, Immunology and Rheumatology  
Clinical Research Coordinator; Salt Lake City Utah
- 2018-Present University of Utah Department of Pediatrics, Division of Allergy, Immunology and Rheumatology  
Research Manager; Salt Lake City Utah

### **Honors**

- 2008-2012 University of Utah Dean's List

### **Other Experience and Certifications**

- 2012 Certified Phlebotomy Technician, *Phlebotomy Training Specialists*
- 2013 Human Subject Research Training Curriculum, *Research Administration Training, University of Utah*
- 2014 Shipping Category B Infectious Substances and Dry Ice, *Research Administration Training, University of Utah*
- 2014 Clinical Research Curriculum Certificate, *Research Administration Training, University of Utah*
- 2015 Certified Clinical Research Professional (CCRP), *Society of Clinical Research Associates*

### **C. Contributions to Science**

As a student, I assisted several Principle Investigators with their projects in the Emergency Department of Primary Children's Hospital by screening, coordinating with Physicians and hospital staff to obtain informed consent, and enrolling subjects into various different research studies that included research on subjects such as asthma, cancer, appendicitis and concussion. As a professional, I have worked with Rheumatology, Immunology and Allergy so the research projects below reflect these subjects, with the exception of one study I have worked on in the Infectious Disease division.

Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HyQvia in Pediatric Subjects with Primary immunodeficiency Diseases  
Baxalta/Shire-161503

anaSTILLs: a randomized, double-blind, placebo-controlled, multicenter, phase 3 efficacy and safety study of subcutaneous anakinra (Kineret) in patients with Still's disease (SJIA and AOSD)  
Swedish Orphan Biovitrum-Sobi.ANAKIN-301

Real World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4-17 (RAMSES)  
Alimmune Therapeutics-ARC007

Secukinumab -A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis  
Novartis-(AIN457)

A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to biologic or non-biologic Disease modifying Anti-Rheumatic Drugs (DMARDs)  
Bristol-Myers Squibb-Protocol IM101-301

A Phase IIa, International, Multi-center, Open-label, Uncontrolled Study to Evaluate the Safety and Pharmacokinetics of 4 x 375 mg/m<sup>2</sup> Intravenous Rituximab in Pediatric Patients with Severe Granulomatosis with Polyangiitis (Wegener's) or Microscopic Polyangiitis

Roche/Genentech-Protocol WA25615

A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases  
Bio Products Laboratory-GMX07

A Phase Ib, Open-label, Multi-center, Study to investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration in Patients with Polyarticular Course Juvenile Idiopathic Arthritis  
Roche/Genentech-Protocol WA28117

A Phase Ib, Open-label, Multi-center, Study to investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration in Patients with Systemic Juvenile Idiopathic Arthritis  
Roche/Genentech-Protocol WA28118

Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients with Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis  
Roche/Genentech-Protocol WA29231

A Phase III, Multicenter, Open-Label Study to evaluate the Pharmacokinetics and Safety of Subgam-VF in Primary Immunodeficiency Diseases (PID)  
Bio Products Laboratory-SCIG03

PEPR-A Clinical Validation of PROMIS Pediatric Measures among youth with JIA/SLE  
National Institutes of Health  
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Investigation of Pediatric Onset Discoid Lupus (DLE)  
Childhood Arthritis and Rheumatology Research Alliance

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)  
Baxalta/Shire-161406

ArChiVe/PedsVas: A Registry for Children with Vasculitis: e-entry; Implementation of a US/Canadian Diagnostic Registry of Children with Chronic Vasculitis  
BC Children's Hospital

A Long-term, Multi-center, Longitudinal Post-marketing, Observational Registry to Assess Long-Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children with Moderately to Severely Active Polyarticular or Polyarticular Course Juvenile Idiopathic Arthritis (JIA) – *STRIVE*  
AbbVie-Protocol P10-262

BrainWorks: The International Childhood CNS Vasculitis and Inflammatory Brain Diseases Outcome Study  
SickKids-The Hospital for Sick Children

An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis  
Bristol-Myers Squibb-Protocol IM101240

Childhood Arthritis and Rheumatology Research Alliance-CARRA Registry  
National Institutes of Health  
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)-Protocol CRNT\_REGST01

The Learning Cohort  
Boston Children's Hospital: Coordinating Center  
University of Utah Department of Pediatrics; Division of Rheumatology/Immunology

Hackensack University Medical Center  
Seattle Children's Hospital  
National Institutes of Health National Library of Medicine

Outcomes of Childhood-Onset Systemic Erythematosus: The Pediatric Lupus Outcomes Study (PLOS)  
University of Utah Department of Pediatrics; Division of Rheumatology/Immunology

Clinical Genetics Research Program: Phenotyping Core and Detailed Characterization of Cytogenetic Abnormalities  
University of Utah Health Sciences Center Department of Medical Genetics

Genetic Analysis of Juvenile Idiopathic Arthritis  
University of Utah Department of Pediatrics; Division of Rheumatology/Immunology  
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Molecular Defects in Immune Disorders  
University of Utah Department of Pediatrics; Division of Rheumatology/Immunology

Pediatric Uveitis  
University of Utah Department of Pediatrics; Division of Rheumatology/Immunology

A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders-6901  
Rare Diseases Clinical Research Network; Primary Immune Deficiency Treatment Consortium  
National Childhood Cancer Foundation

A retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January1, 1968-6902  
Rare Diseases Clinical Research Network; Primary Immune Deficiency Treatment Consortium  
NIH National Institute of Allergy and Infectious Disease

Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995-6903  
Rare Diseases Clinical Research Network; Primary Immune Deficiency Treatment Consortium  
NIH National Institute of Allergy and Infectious Disease

Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990-6904  
Rare Diseases Clinical Research Network; Primary Immune Deficiency Treatment Consortium  
NIH National Institute of Allergy and Infectious Disease

Clinical, Social, and Economic Impacts of Pediatric Outpatient Antimicrobial Regimens  
University of Utah Department of Pediatrics; Division of Infectious Disease  
NIH National Institute of Child Health and Human Development

**D. Additional Information: Research Support and/or Scholastic Performance**